FDA Approves Pfizer (NYSE: PFE) Prevnar 13 Bacteria Vaccine

The U.S. Food and Drug Administration approved the Pfizer Inc. (NYSE: PFE) vaccine Prevnar 13 as a follow up vaccine of Prevnar.

The vaccines protect children from the age of 6 weeks to 5 years old from bacteria that can cause serious illnesses, such as as meningitis, acute ear infections, bacteremia and sepsis.

The U.S. Advisory Committee on Immunization Practices advised that children under the age of 5 who have already received four doses of Pfizer Inc's Prevnar vaccine should get a dose of the new version, which covers more strains of pneumonia causing bacteria.